PriceTargets.com logo

Taysha Gene Therapies - TSHA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.57
  • Forecasted Upside: 124.28%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$2.93 As of 05/20/2025 05:00 PM ET
▲ +0.14 (5.02%)

This chart shows the closing price for TSHA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Taysha Gene Therapies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TSHA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TSHA

Analyst Price Target is $6.57
▲ +124.28% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Taysha Gene Therapies in the last 3 months. The average price target is $6.57, with a high forecast of $9.00 and a low forecast of $5.00. The average price target represents a 124.28% upside from the last price of $2.93.

This chart shows the closing price for TSHA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 7 polled investment analysts is to buy stock in Taysha Gene Therapies. This rating has held steady since January 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/27/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/25/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/25/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/23/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/19/2025
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/20/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/20/2025

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/16/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$8.00 ➝ $9.00
4/28/2025JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$5.00 ➝ $5.00
4/28/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$7.00 ➝ $7.00
4/10/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
2/27/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
2/26/2025Chardan CapitalReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
1/6/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
11/15/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$6.00 ➝ $8.00
11/14/2024Chardan CapitalReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
11/12/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$5.00 ➝ $5.00
11/12/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$7.00 ➝ $7.00
11/12/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
8/14/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$7.00 ➝ $6.00
8/13/2024Chardan CapitalReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
8/12/2024Needham & Company LLCLower TargetBuy ➝ Buy$7.00 ➝ $6.00
7/23/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
7/1/2024Piper SandlerLower TargetOverweight ➝ Overweight$9.00 ➝ $7.00
6/27/2024BMO Capital MarketsInitiated CoverageOutperform$5.00
6/20/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$5.00 ➝ $5.00
6/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$7.00 ➝ $7.00
6/18/2024Chardan CapitalReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
6/17/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
5/28/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$7.00 ➝ $7.00
5/15/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$7.00
5/15/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$7.00
5/14/2024Jefferies Financial GroupReiterated RatingHold ➝ Buy$2.00 ➝ $8.00
5/2/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$7.00
4/30/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$7.00
4/18/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$7.00
4/11/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$7.00
4/9/2024Piper SandlerInitiated CoverageOverweight$9.00
3/21/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$7.00
3/21/2024Chardan CapitalBoost TargetBuy ➝ Buy$5.00 ➝ $7.00
3/20/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$5.00
3/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$7.00
3/20/2024Needham & Company LLCBoost TargetBuy ➝ Buy$5.00 ➝ $7.00
2/29/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$5.00
12/18/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$7.00
11/15/2023Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$6.00 ➝ $7.00
9/20/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$5.00
9/20/2023Canaccord Genuity GroupLower TargetBuy ➝ Buy$7.00 ➝ $6.00
9/20/2023Truist FinancialLower TargetBuy ➝ Buy$6.00 ➝ $5.00
8/16/2023Canaccord Genuity GroupLower TargetBuy ➝ Buy$13.00 ➝ $7.00
8/15/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$4.00
8/15/2023Truist FinancialBoost TargetBuy ➝ Buy$2.00 ➝ $6.00
8/15/2023Needham & Company LLCLower TargetBuy ➝ Buy$6.00 ➝ $5.00
8/15/2023Chardan CapitalReiterated RatingBuy ➝ Buy$5.00
8/15/2023Robert W. BairdBoost TargetOutperform ➝ Outperform$6.00 ➝ $8.00
8/14/2023Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$2.00 ➝ $7.00
3/30/2023JMP SecuritiesReiterated RatingMarket Outperform$4.00
3/30/2023Cantor FitzgeraldLower TargetOverweight$13.00 ➝ $2.00
3/29/2023Chardan CapitalLower TargetBuy$6.00 ➝ $5.00
3/29/2023Needham & Company LLCReiterated RatingBuy$6.00
3/29/2023Truist FinancialLower TargetBuy$4.00 ➝ $3.00
2/2/2023BTIG ResearchDowngradeBuy ➝ Neutral
2/1/2023Canaccord Genuity GroupLower TargetBuy$17.00 ➝ $13.00
2/1/2023Cantor FitzgeraldReiterated RatingOverweight$24.00 ➝ $13.00
2/1/2023Truist FinancialLower TargetBuy$15.00 ➝ $4.00
2/1/2023Chardan CapitalLower TargetBuy$16.00 ➝ $6.00
2/1/2023JMP SecuritiesLower TargetMarket Outperform$6.00 ➝ $4.00
2/1/2023Needham & Company LLCLower TargetBuy$16.00 ➝ $6.00
2/1/2023Robert W. BairdLower TargetOutperform$10.00 ➝ $6.00
2/1/2023Jefferies Financial GroupDowngradeBuy ➝ Hold
1/27/2023Morgan StanleyDowngradeOverweight ➝ Equal Weight$23.00 ➝ $3.00
1/19/2023JMP SecuritiesLower TargetMarket Outperform$20.00 ➝ $6.00
1/4/2023Wells Fargo & CompanyLower TargetOverweight$14.00 ➝ $10.00
12/21/2022Cantor FitzgeraldReiterated RatingOverweight
11/14/2022Wells Fargo & CompanyLower Target$20.00 ➝ $14.00
11/10/2022JMP SecuritiesLower TargetMarket Outperform$22.00 ➝ $20.00
11/10/2022BTIG ResearchLower Target$25.00 ➝ $15.00
11/9/2022Chardan CapitalLower TargetBuy$32.00 ➝ $16.00
11/9/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral
11/8/2022GuggenheimLower Target$22.00 ➝ $19.00
11/8/2022Needham & Company LLCLower TargetBuy$18.00 ➝ $16.00
11/8/2022Canaccord Genuity GroupInitiated CoverageBuy ➝ Buy$16.00
10/26/2022Truist FinancialLower Target$35.00 ➝ $15.00
10/26/2022Robert W. BairdLower TargetOutperform$26.00 ➝ $21.00
10/25/2022Needham & Company LLCLower TargetBuy$20.00 ➝ $18.00
8/12/2022Chardan CapitalLower TargetBuy$34.00 ➝ $32.00
8/12/2022WedbushLower TargetOutperform$9.00 ➝ $5.00
5/24/2022The Goldman Sachs GroupLower TargetBuy$27.00 ➝ $16.00
5/17/2022Chardan CapitalLower Target$37.00 ➝ $34.00
5/17/2022GuggenheimLower TargetNA$22.00
5/17/2022Needham & Company LLCLower TargetBuy$20.00
4/1/2022Truist FinancialLower TargetBuy$60.00 ➝ $35.00
4/1/2022Needham & Company LLCLower TargetBuy$47.00 ➝ $32.00
4/1/2022JMP SecuritiesLower TargetMarket Outperform$44.00 ➝ $36.00
4/1/2022The Goldman Sachs GroupLower TargetBuy$34.00 ➝ $27.00
3/31/2022Chardan CapitalLower Target$60.00 ➝ $37.00
3/9/2022Robert W. BairdInitiated CoverageOutperform$26.00
3/1/2022Wells Fargo & CompanyInitiated CoverageOverweight$25.00
2/18/2022Sumitomo Mitsui Financial GroupInitiated CoverageOutperform$25.00
2/1/2022JMP SecuritiesReiterated RatingBuy$44.00
1/14/2022JMP SecuritiesReiterated RatingBuy$38.00
12/16/2021GuggenheimInitiated CoverageBuy$28.00
12/2/2021Needham & Company LLCReiterated RatingBuy$47.00
11/11/2021JMP SecuritiesLower TargetMarket Outperform$40.00 ➝ $38.00
10/28/2021JMP SecuritiesReiterated RatingBuy$40.00
10/6/2021Needham & Company LLCBoost Target$45.00 ➝ $47.00
9/24/2021JMP SecuritiesReiterated RatingBuy$40.00
9/23/2021William BlairReiterated RatingBuy
8/31/2021BTIG ResearchReiterated RatingBuy$44.00
8/31/2021JMP SecuritiesReiterated RatingBuy$40.00
8/18/2021Morgan StanleyLower TargetOverweight$43.00 ➝ $39.00
8/17/2021Chardan CapitalLower TargetBuy$67.50 ➝ $60.00
7/15/2021Needham & Company LLCInitiated CoverageBuy$45.00
7/1/2021Chardan CapitalReiterated RatingBuy
6/24/2021Truist FinancialInitiated CoverageBuy$60.00
6/14/2021BTIG ResearchInitiated CoverageBuy$44.00
6/9/2021WedbushInitiated CoverageOutperform$31.00
6/8/2021JMP SecuritiesInitiated CoverageOutperform$40.00
5/19/2021Cantor FitzgeraldInitiated CoverageOverweight$44.00
4/26/2021Chardan CapitalReiterated RatingBuy
4/13/2021Morgan StanleyBoost TargetOverweight$30.00 ➝ $43.00
4/12/2021Chardan CapitalBoost TargetBuy$60.00 ➝ $67.50
3/8/2021Morgan StanleyBoost TargetOverweight$29.00 ➝ $30.00
3/4/2021Chardan CapitalBoost TargetBuy$45.00 ➝ $60.00
2/23/2021William BlairInitiated CoverageOutperform$46.00
1/4/2021OppenheimerInitiated CoverageOutperform$42.00
10/19/2020Chardan CapitalInitiated CoverageBuy$45.00
10/19/2020Jefferies Financial GroupInitiated CoverageBuy$34.00
10/19/2020Morgan StanleyInitiated CoverageOverweight$29.00
10/19/2020The Goldman Sachs GroupInitiated CoverageBuy$31.00
(Data available from 5/20/2020 forward)

News Sentiment Rating

0.92 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 7 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 6 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2025
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2025
  • 4 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
3/21/2025
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/20/2025
  • 16 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/20/2025

Current Sentiment

  • 16 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Taysha Gene Therapies logo
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Read More

Today's Range

Now: $2.93
Low: $2.75
High: $3.00

50 Day Range

MA: $1.76
Low: $1.13
High: $2.93

52 Week Range

Now: $2.93
Low: $1.05
High: $4.32

Volume

5,773,165 shs

Average Volume

2,876,907 shs

Market Capitalization

$600.81 million

P/E Ratio

4.65

Dividend Yield

N/A

Beta

0.9

Frequently Asked Questions

What sell-side analysts currently cover shares of Taysha Gene Therapies?

The following Wall Street analysts have issued stock ratings on Taysha Gene Therapies in the last year: BMO Capital Markets, Canaccord Genuity Group Inc., Cantor Fitzgerald, Chardan Capital, JMP Securities, Needham & Company LLC, and Piper Sandler.
View the latest analyst ratings for TSHA.

What is the current price target for Taysha Gene Therapies?

0 Wall Street analysts have set twelve-month price targets for Taysha Gene Therapies in the last year. Their average twelve-month price target is $6.57, suggesting a possible upside of 124.3%. Canaccord Genuity Group Inc. has the highest price target set, predicting TSHA will reach $9.00 in the next twelve months. BMO Capital Markets has the lowest price target set, forecasting a price of $5.00 for Taysha Gene Therapies in the next year.
View the latest price targets for TSHA.

What is the current consensus analyst rating for Taysha Gene Therapies?

Taysha Gene Therapies currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TSHA will outperform the market and that investors should add to their positions of Taysha Gene Therapies.
View the latest ratings for TSHA.

What other companies compete with Taysha Gene Therapies?

Other companies that are similar to Taysha Gene Therapies include Mirum Pharmaceuticals, Apellis Pharmaceuticals, Arrowhead Pharmaceuticals, Vericel and NewAmsterdam Pharma. Learn More about companies similar to Taysha Gene Therapies.

How do I contact Taysha Gene Therapies' investor relations team?

Taysha Gene Therapies' physical mailing address is 2280 Inwood Road, DALLAS TX, 75235. The company's listed phone number is 214-612-0000 and its investor relations email address is [email protected]. The official website for Taysha Gene Therapies is www.tayshagtx.com. Learn More about contacing Taysha Gene Therapies investor relations.